First Tracks Biotherapeutics Stock Climbs Nearly 8% as Celiac Drug Hopes Push Shares Up 160% in a Year
First Tracks Biotherapeutics Inc. (TRAX) shares rose 8% to $53.57, extending a 160% year-to-date gain. The rally follows positive Phase 1b trial results for its celiac disease drug, ANB033, which showed significant protection against intestinal damage. The company has no new updates but plans late-stage development in 2027. TRAX is valued at $2.2B and reported a Q3 net loss of $31.4M.

